New technologies for making vaccines

Vaccine

Volumn 17, Issue 13-14, 1999, Pages 1596-1604

  Ellis, Ronald W ^a  

^a BioChem Pharma Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; VACCINE;

CONFERENCE PAPER; IMMUNOREGULATION; MARKETING; PATHOGENESIS; PRIORITY JOURNAL; VACCINATION;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; DNA, RECOMBINANT; HUMANS; VACCINES; VACCINES, COMBINED; VACCINES, SYNTHETIC;

EID: 0344141397     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00416-2     Document Type: Conference Paper

References (52)

1. Sabin A.B., Boulger L.R. History of Sabin attenuated poliovirus vaccine. J. Biol. Stand. 1:1973;115-118.
2. Stokes J., Weibel R.E., Villarejos V.M., Arguedes G., Buynak E.B., Hilleman M.R. Trivalent combined measles-mumps-rubella vaccine. Findings in clinical-laboratory studies. J. Am. Med. Assoc. 218:1971;57-61.
3. Maassab H.F., DeBorde D.C. Development and characterization of cold-adapted viruses for use as live virus vaccines. Vaccine. 3:1985;355-371.
4. McKay E., Higgins P., Tyrrell D., Pringle C. Immunogenicity and pathogenicity of temperature-sensitive modified respiratory syncytial virus in adult volunteers. J. Med. Virol. 25:1988;411-421.
5. Henderson D.A. Smallpox eradication. Proc. R. Soc. London. 199:1977;83-97.
6. Vesikari T., Kapikian A.Z., Delem A., Zissis G. A comparative trial of Rhesus monkey (RRV-1) and bovine (RIT 4237) oral rotavirus vaccines in young children. J. Infect. Dis. 153:1986;832-839.
7. Rennels M.B., Glass R.I., Dennehy P.H., Dernstein D.I., Pichichero M.E., Zito E.T., Mack M.E., Davidson B.L., Kapikian A.Z. Safety and efficacy of high-dose Rhesus-human reassortant rotavirus vaccines: report of the national multicenter trial. Pediatrics. 97:1996;7-13.
8. McLean C.S., Challanain N., Duncan I., Boursnell M.E., Jennings R., Inglis S.C. Induction of a protective immune response by mucosal vaccination with a DISC HSV-1 vaccine. Vaccine. 14:1996;987-992.
9. Perales M.A., Schwartz D.H., Fabry J.A., Lieberman J. A vaccinia-gp160-based vaccine but not a gp160 vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees. J. AIDS Hum. Retrovir. 10:1995;27-35.
10. Leong K.H., Ramsay A.J., Boyle D.B., Ramshaw I.A. Selective induction of immune responses by cytokines coexpressed in recombinant fowlpox virus. J. Virol. 68:1994;8125-8130.
11. Graham FL, Prevec L. Adenovirus-based expression vectors and recombinant vaccines. In: Ellis R, editor. Vaccines: New approaches to immunological problems. New York, NY: Marcel Dekker, 1992. p. 363-90.
12. Schlesinger S. Alphaviruses-vectors for the expression of heterologous genes. Trends Biotechnol. 11:1993;18-22.
13. Weill-Halle B. Oral vaccination. In: Rosenthal SR, editor. BCG vaccination against tuberculosis. Boston: Little, Brown, 1957.
14. Germanier R., Furer E. Isolation and characterization of galE mutant Ty21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. J. Infect. Dis. 131:1975;553-558.
15. Levine M.M., Black R.E., Ferreccio C., Germanier R. Clinical Typhoid Committee. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet. 2:1987;1049-1052.
16. Tacket C.O., Losonsky G., Nataro J.P., Cryz S.J., Edelman R., Kaper J.B., Levine M.M. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. J. Infect. Dis. 166:1992;837-841.
17. Gonzalez C., Hone D., Noriega F.R., Tacket C.O., Davis J.R., Losonsky G., Nataro J.P., Hoffman S., Malik A., Nardin E., Sztein M.B., Heppner G., Fouts T.R., Isibasi A., Levine M.M. Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans. J. Infect. Dis. 169:1994;927-931.
18. Stover C.K., de la Cruz V.F., Fuerst T.R., Burlein J.E., Benson L.A., Bennett L.T., Bansal G.P., Young J.F., Lee M.H., Hatfull G.F., Snapper S.B., Barletta R.G., Jacobs W.R., Bloom B.R. New use of BCG for recombinant vaccines. Nature. 351:1991;456-460.
19. Vogel FR, Powell MF. A compendium of vaccine adjuvants and excipients. In: Powell MF, Newman MJ, editors. Vaccine design. The subunit and adjuvant approach. New York, NY: Plenum Press, 1996. p. 141-228.
20. Werzberger W.A., Mensch B., Kuter B., Brown L., Lewis J., Sitrin R., Miller W., Shouval D., Wiens B., Calandra G., Ryan J., Provost P., Nalin D. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N. Engl. J. Med. 327:1992;453-457.
21. Cherry J.D., Brunell P.A., Golden G.S., Karzon D.T. Report of the task force on pertussis and pertussis immunization, 1988. Pediatrics. 81:1988;939.
22. Clemens J.D., Sack D.A., Harris J.R., van Loon F., Chakraborty J., Ahmed F., Rao M.R., Khan M.R., Yunus M.D., Huda N., Stanton B.F., Kay B.A., Walter S., Ecckels R., Svennerholm A.-M., Holmgren J. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet. 355:1990;270-273.
23. Murdin A.D., Barreto L., Plotkin S. Inactivated polio vaccines: past and present experience. Vaccine. 14:1996;735-746.
24. Crawford C.R., Faiza A.M., Mukhlis F.A., Jennings R., Oxford J.S., Hockley D.J., Potter C.W. Use of zwitterionic detergent for the preparation of an influenza virus vaccine. 1. Preparation and characterization of disrupted virions. Vaccine. 2:1984;193-198.
25. Hilleman MR, Bertland AU, Buynak EB, Lampson GP, McAleer WJ, McLean AA, Roehm RR, Tytell AA. Clinical and laboratory studies of HBsAg vaccine. In: Vyas GN, Cohen SN, Schmid R, editors. Viral hepatitis. Philadelphia, PA: Franklin Institute Press, 1978. p. 525-41.
26. Plotkin S.A., Cadoz M. The acellular pertussis vaccine trials: an interpretation. Pediatr. Infect. Dis. J. 16:1997;508-517.
27. Jones F.G., Moss J.M. Studies on tetanus toxoid. I. The antitoxic titer of human subject following immunization with tetanus toxoid and tetanus alum precipitated toxoid. J. Immunol. 30:1936;115-125.
28. Ramon G. Sur le pouvoir floculant et sur les proprietes immunisantes d'une toxin diphterique rendue anatoxique (anatoxine). C. R. Acad. Sci. 177:1923;1338-1340.
29. Nencioni L., Pizza M.G., Bugnoli M., De Magistris M.T., Di Tommaso A., Giovannoni F., Manetti R., Marsili I., Matteucci G., Nucci D., Olivieri R., Pileri P., Presentini R., Villa L., Kreefrenberg J., Silvestriss G., Tagliabue A., Rappuoli R. Characterization of genetically inactivated pertussis toxin mutants: candidates for a new vaccine against whooping cough. Infect. Immun. 58:1990;1308-1315.
30. Valenzuela P., Medina A., Rutter W.J., Ammerer G., Hall B.D. Synthesis and assembly of hepatitis B virus surface-antigen particles in yeast. Nature. 298:1982;347-350.
31. Jansen K.U., Rosolowsky M., Schultz L.D., Markus H.Z., Cook J.C., Donnelly J.J., Martinez D., Ellis R.W., Shaw A.R. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine. 13:1995;1509-1514.
32. Keller R.J., Eisenbarth G.S., Jackson R.A. Insulin prophylaxis of individuals at risk of type-1 diabetes. Lancet. 341:1993;927-928.
33. Kingsman S.M., Kingsman A.J. Polyvalent recombinant antigens: a new vaccine strategy. Vaccine. 6:1988;304-306.
34. Vreden S.G.S., Oettinger T., Sauerwein R.W., Meuwissen J.H.E. Phase I clinical trial of a recombinant malaria vaccine consisting of the circumsporozoite repeat region of Plasmodium falciparum coupled to hepatitis B surface antigen. Am. J. Trop. Med. Hyg. 45:1991;533-538.
35. Herrington D.A., Clyde D.F., Losonsky G., Cortesta M., Murphy J.R., Davis J., Bargar S., Felix A.M., Heimer E.P., Gillessen D., Nardini E., Nussenzweig R.S., Nussenzweig V., Hollingdale M.R., Levine M.M. Safety and immunogenicity in man of a synthetic peptide in malaria vaccine against Plasmodium falciparum sporozoites. Nature. 328:1987;257-259.
36. Vitiello A., Ishioka G., Grey H.M., Rose R., Farness P., LaFond R., Yuan L., Chisari F.V., Furze J., Bartholomeuz R., Chesnut R.W. Development of a lipopeptide-based therapeutic vaccine to treat chronic hepatitis B infection. I. Induction of a primary cytotoxic T-lymphocyte response in humans. J. Clin. Invest. 95:1996;341-349.
37. Gjertsen M.K., Bjorheim J., Saeterdal I., Myklebust J., Gaudernack G. Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. Int. J. Cancer. 72:1997;784-790.
38. Gotschlich E.C., Liu T.Y., Artenstein M.S. Human immunity to the meningococcus. III. Preparation and immunochemical properties of the group A, group B and group C meningococcal polysaccharides. J. Exp. Med. 129:1969;1349-1365.
39. Kass E.G. Assessment of the pneumococcal polysaccharide vaccine. Rev. Infect. Dis. 3:1981;S1-S197.
40. Kniskern PJ, Marburg S, Ellis RW. Haemophilus influenzae type b conjugate vaccines. In: Powell M, Newman M, editors. Vaccine design: The subunit approach. New York, NY: Plenum Publishing Corporation, 1995. p. 673-94.
41. Ahman H., Kayhty H., Tamminen P., Vuorela A., Malinoski F., Eskola J. Pentavalent pneumococcal oligosaccharide conjugate vaccine PnCRM is well tolerated and able to induce an antibody response in infants. Pediatr. Infect. Dis. J. 15:1996;134-139.
42. Kennedy R.C., Adler-Storthz K., Henkel R.D., Sanchez Y., Melnick J.L., Dreesman G.R. Immune response to hepatitis B surface antigen: enhancement by prior injection of antibodies to the idiotype. Science. 221:1983;853-855.
43. Herlyn D., Wettendorff M., Iliopoulos D., Schmoll E., Schedel I., Koprowski H. Modulation of cancer patients' immune responses by administration of anti-idiotypic antibodies. Viral Immunol. 2:1989;271-276.
44. Wolff J.A., Malone R.W., Williams P., Chong W., Acsadi G., Jani A., Felgner P.L. Direct gene transfer into mouse muscle in vivo. Science. 247:1990;1465-1468.
45. Dubensky T.W., Driver D.A., Polo J.M., Bell B.A., Latham E.M., Ibanez C.E., Chada S., Brumm D., Banks T.A., Mento S.J., Jolly D.J., Chang S.M.W. Sindbis virus DNA-based expression vectors: utility for in vitro and in vivo gene transfer. J. Virol. 70:1996;508-519.
46. Williams R.S., Johnston S.A., Riedy M., DeVit M.J., McElligott S.G., Sanford J.C. Introduction of foreign genes into tissues of living mice by DNA-coated microprojectiles. Proc. Natl. Acad. Sci. USA. 88:1991;2726-2730.
47. Remy J.-S., Sirlin C., Vierling P., Behr J.-P. Gene transfer with a series of lipophilic DNA-binding molecules. Bioconjugate Chem. 5:1994;647-654.
48. Coney L., Wang B., Ugen K.E., Boyer J., McCallus D., Srikantan V., Agadjanyan M., Pachuk C.J., Herold K., Merva M., Gilbert L., Deng K., Moelling K., Newman M., Williams W.V., Weiner D.B. Facilitated DNA inoculation induces anti-HIV-1 immunity in vivo. Vaccine. 12:1994;1545-1550.
49. Krieg A.M., Yi A.-K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., Koretzky G.A., Klinman D.M. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 374:1995;546-549.
50. Kent S.J., Stallard V., Corey L., Hu S.-L., Morton W.R., Gritz L., Panicali D.L., Greenberg P.D. Analysis of cytotoxic T-lymphocyte responses to SIV proteins in SIV-infected macaques using antigen-specific stimulation with recombinant vaccinia and fowlpox viruses. AIDS Res. Hum. Retrovirol. 10:1994;551-560.
51. Sizemore D.R., Branstrom A.A., Sadoff J.C. Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science. 270:1996;299-302.
52. Clemens J.D., Sack D.A., Harris J.R., Chakraborty J., Khan M.R., Stanton B.F., Ali M., Ahmed F., Yunus M., Kay B.A., Khan M.U., Rao M.R., Svennerholm A.-M., Holmgren J. Impact of B subunit killed whole-cell and killed whole-cell-only oral vaccines against cholera upon treated diarrhoeal illness and mortality in an area endemic for cholera. Lancet. 1:1988;1375-1379.